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We report the ﬁrst case of Ramsay Hunt syndrome (RHS) diagnosed after kidney
transplantation in Korea. RHS is a disease caused by latent varicella-zoster charac-
terized to involve geniculate ganglion of the seventh cranial nerve. Patients who
have undergone kidney transplantation can be easily affected by viral infections
because of their immune-compromised status. A 35-year-old man with hyperten-
sive end-stage renal disease underwent kidney transplantation. Two months after
surgery, the recipient was diagnosed with RHS and treated with antivirals and
steroids. However, after using the antiviral agents for the recommended duration,
facial paralysis occurred as a new presentation and he required further treatment.
Otalgia and periauricular vesicles improved, but the facial palsy remained.
Copyright © 2015. The Korean Society of Nephrology. Published by Elsevier Ltd. This
is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Latent infection of varicella-zoster virus (VZV) is an issue in
managing kidney transplant recipients. Because these patients
are using various combinations of immunosuppressive agents,
incidence of severe forms of viral infection is reported relatively
high compared with that of normal immune status. Ramsay
Hunt syndrome (RHS), also known as herpes oticus, is a rare
manifestation of latent VZV infection and was ﬁrst described by
Ramsey Hunt [1]. This syndrome is caused by the reactivation
of latent VZV in geniculate ganglion of the seventh cranial
nerve and is characterized by otalgia, vesicle, and facial palsy of
the affected side. RHS occurs more commonly in immunosup-
pressed individuals, such as kidney transplant recipients [2,3],y, Department of Internal
dicine, 45 Kyungheedae-
ee).
iety of Nephrology. Published
y-nc-nd/4.0/).but it has not been reported previously in Korea. Here, we
describe the ﬁrst case of RHS diagnosed and treated with
antiviral agents and glucocorticoids in a 35-year-old kidney
transplant recipient in Korea.
Case report
A 35-year-old kidney transplant recipient presented to the
nephrology outpatient clinic because of left otalgia and peri-
auricular vesicles. He underwent deceased-donor kidney
transplantation because of hypertensive end-stage renal dis-
ease about 2 months before the ﬁrst symptoms appeared and
had been using immunosuppressive medications. His regimen
included tacrolimus 3 mg, mycophenolic acid 720 mg twice
daily, and prednisolone 20 mg once daily. At the time of
transplantation, we checked his viral markers as a protocol, and
the patient did not recall his vaccination status. He underwent
emergency surgery before we checked the ﬁnal result of the
viral markers. Later, we found out that his serum VZV immu-
noglobulin (Ig)-G was positive and IgM was negative (Fig. 1).by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
Figure 1. Clinical course of the patient. Bid, twice a day; Day, days from the onset of otalgia; IV, intravenously; MPA, mycophenoleic acid; MPDL,
methylprednisolone; PCR, polymerase chain reaction; qd, once a day; VZV, varicella-zoster virus.
Kidney Res Clin Pract 34 (2015) 241e244242Initial vital signs were stable. In addition to pain and vesic-
ular rash around the left ear, he complained of numbness of the
left half of his face, but neurologic examination revealed no
abnormal ﬁndings. Routine laboratory tests were conducted
and revealed a serum creatinine level of 1.9 mg/dL. EstimatedM P N S
208bp M: Marker(50bp)
P: Positive control
N: Negative control
S: Patient’s sample
Figure 2. Result of varicella-zoster virus polymerase chain reaction
from the serum of the patient.glomerular ﬁltration rate was calculated using the Modiﬁcation
of Diet in Renal Disease equation, and the valuewas 48 mL/min.
The tacrolimus level was measured immediately before inges-
tion, and the result was 4.8 ng/mL, which was slightly below
the target range.
In addition, serum VZV IgG/IgM was measured, and serum
VZV polymerase chain reaction (PCR) was performed (Fig. 2).
However, his symptoms were sufﬁciently clear to make a
diagnosis of RHS with or without serologic conﬁrmation of VZV
infection, and we were not reluctant to administer intravenous
(i.v.) antiviral agents and steroids in this case. Acyclovir was
administered at a dose of 500 mg i.v. (5 mg/kg, 95 kg) twice
daily for 5 days. The preferred dose of acyclovir in patients with
normal renal function is 5e12.4 mg/kg twice daily. However,
considering his renal impairment, dose reduction was per-
formed. To administer steroids via the i.v. route and considering
an anti-inﬂammatory effect, methylprednisolone was chosen.
Methylprednisolone 62.5 mg was given i.v. and then tapered
out. Although serum VZV IgM was negative, a positive result
Table 1. Literature review of Ramsay Hunt syndrome after kidney transplantation
No. Age/sex 1. Onset after KT Immunosuppressant Treatment
2. Donor
3. Cause of ESRD
1 [3] 36/F 1. l mo 1. MMF 1,500 mg IV Acyclovir (3 mg/kg, 3 times/d)
Reduction of the MMF dose
from 1,500 mg/d to 1,000 mg/d
PO prednisolone 50mg for 3 days
2. Living donor 2. Tacrolimus 6 mg
3. Polycystic kidney disease
2 [2] 41/M 1. 4 yr 1. MMF 1,500 mg IV Acyclovir (10 mg/kg, 3 times/d)
Myringectomy with tube placement in the left
middle ear
Oral prednisone
2. Living donor 2. Tacrolimus 2.6 mg bid
3. IgAN
Valacyclovir 1,000 mg 3 times/d
3 [11] 35/M 1. 8 mo 1. MPA 1,440 mg IV Acyclovir (250 mg, 3 times/d)
2. Not mentioned 2. Tacrolimus 2.5 mg/d IV Methylprednisolone (100 mg, 1 time/d)
3. Unknown etiology Reduction of the MMF dose
from l,440 mg/d to 720 mg/d
4 [12] 27/M 1. 18 mo 1. MMF 2,000 mg IV Acyclovir 10 mg/kg/d, 3 times/d
PO Acyclovir (400 mg. 5 times/d)
Oral prednisolone dosage was tapered
2. Living donor 2. Cyclosporin
3. Not mentioned
Bid, twice a day; ESRD, end-stage renal disease; IgAN, immunoglobulin-A nephropathy; IV, intravenously; KT, kidney transplantation; MMF, myco-
phenolate mofetil; MPA, mycophenolic acid; PO, oral.
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conﬁrmed. As symptoms improved, the patient was discharged
with oral antivirals and prednisolone. He was treated with
famciclovir 750 mg once daily for an additional 10 days along
with a maintenance dose of prednisolone (20 mg once daily).
However, 3 days after cessation of famciclovir, he returned to
the hospital because of a sudden onset of a severe spinning-
type dizziness associated with nausea and left facial palsy.
Neurologic examinations were conducted again, and
nystagmus was observed at the primary position. When we
evoked the nystagmus using the DixeHallpike test, left
torsional nystagmus was observed in both eyes. In addition, on
testing his facial paralysis, forehead blinking was decreased.
These observations indicated that facial palsy was a result of
peripheral nerve abnormality, but brain magnetic resonance
imaging (MRI) was performed to exclude central vertigo and to
evaluate the swelling of the facial nerve. In both T1- and T2-
weighted images, microbleeding ~9 mm in size was noted in
the right pons. However, judging from its signal intensity, it was
a chronic lesion rather than an acute lesion, and current
dizziness was irrelevant. No swelling of the left facial nervewas
seen. We restarted oral famciclovir 750 mg once daily with oral
methylprednisolone for 7 days. This time we used oral meth-
ylprednisolone instead of i.v. because the patient complained of
the i.v. catheter. The starting dose of oral methylprednisolone
was 64 mg which was tapered every 2 days with a reduction of
16 mg each time. In addition, we lowered the dose of myco-
phenolate mofetil from 720 mg twice daily to 540 mg twice
daily. We maintained the dose of tacrolimus because its serum
level was at the lower limit of the therapeutic range. In addition
to medical treatment, we encouraged self-facial massage and
consulted for rehabilitation.
The patient was discharged with a slight improvement of
facial paralysis. Electromyography was conducted 2 weeks after
the onset to evaluate his facial motor and sensory nerves. This
examination showed no abnormal spontaneous activity and
neuropathy action potentials, but reduced recruitment of left
frontalis, orbicularis oculi, nasalis, and orbicularis oris was
noted. Otalgia and periauricular vesicles improved, but left
facial palsy still remained. After 1 month, his facial palsy
showed improvement.Discussion
RHS is a disease caused by latent VSV infection involving the
geniculate ganglion of the seventh cranial nerve [1]. Kidney
transplant patients can be easily affected by viruses and show
severe extents of disease because of immunosuppressive
medications that must be taken [2]. The incidence of VZV
infection is ~11.2% within 4 years after kidney transplantation
[4,5] but that of RHS has not been reported probably due to the
rarity of the disease.
Measuring serum VZV IgG/IgM is essential before the
transplant. A vaccination for seronegative candidates should be
considered if the transplant is elective.
The patient described here showed the RHS symptom triad,
and virologic conﬁrmation was performed using VZV PCR. The
disease was diagnosed easily, but treatment was challenging
because he received a kidney from a donorwith a high creatinine
level (1.8 mg/dL). We considered his estimated glomerular
ﬁltration rate and had to reduce the dose of acyclovir. Typical
brain MRI ﬁndings of RHS include enhancement of the affected
facial nerve as a consequence of destruction of the bloodebrain
barrier [6]. In this case, facial nerve enhancement was not
observed, but evidence of chronic pontine microbleeding was
noted.We performed a brainMRI 14 days after the onset because
his clinical signs and symptoms were compatible with typical
peripheral vertigo. Becauseweusedanantiviral agent and steroid
for the14days, facial nerve swellingmighthavebeen improvedat
the time of the MRI. Preexisting bleeding in the central nervous
systemwas thought to be a consequence of hypertension. RHS is
treated with steroids to reduce the inﬂammation, and a starting
dose of 50e60mg of prednisolone is commonly used along with
an i.v. antiviral agent to suppress virus replication [7e9].
Acyclovir is believed to reduce nerve damage, so its clinical use-
fulness is widely accepted [10]. In addition, adjunctive therapies,
such as facial massage and acupuncture, can be useful, but there
have been no systematic studies to evaluate the effectiveness of
these treatments. However, unlike RHS in normal populations,
there are several additional considerations in treating RHS in
kidney transplant recipients. Posttransplant care for kidney re-
cipients is difﬁcult because care is required in the application of
medications to protect renal function.
Kidney Res Clin Pract 34 (2015) 241e244244Table 1 presents a literature review of RHS after kidney
transplantation. Initial treatment using i.v. acyclovir and ste-
roids (either i.v. or oral) was the same for all cases. All four cases
of patients showed improvement after using acyclovir and
steroids. However, time to achieve remission varied. It ranged
from 10 days to 10 months.
Maintaining the balance between rejection and the oppor-
tunistic infection is always troublesome after organ trans-
plantation. In addition, in treating RHS, methylprednisolone is
used for its anti-inﬂammatory effects, but steroid use can also
suppress the host immunity simultaneously, so there is
increased risk of virus infection. The duration of steroid use and
the reduction of immunosuppressants are dependent on the
clinician׳s decision. This case is worth reporting because it is
the ﬁrst case of RHS diagnosed after kidney transplantation in
Korea.
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